TABLE 3.

FDA approved PD-1 and PDL-1 inhibitor drugs in various types of cancer immunotherapy (78, 116).

Agent	Target	Commercial name	Date of FDA approval/types of cancer treated
Pembrolizumab	PD-1	Keytruda®	9/2014: Melanoma
			10/2015: Non-small cell lung cancer
			8/2016: Head and neck squamous cell carcinoma
			3/2017: Hodgkin lymphoma
			5/2017: Urothelial carcinoma
			5/2017: MSI-H colorectal cancer
			9/2017: Gastric cancer
Nivolumab	PD-1	Opdivo®	12/2014: Melanoma
			11/2015: Renal cell carcinoma
			5/2016: Hodgkin lymphoma
			11/2016: Head and neck squamous cell carcinoma
			2/2017: Urothelial carcinoma
			8/2017: MSI-H colorectal cancer
			9/2017: Hepatocellular carcinoma
Atezolizumab	PDL-1	Tecentriq®	5/2016: Urothelial carcinoma
			10/2016: Non-small cell lung cancer
Avelumab	PDL-1	Bavencio®	3/2017: Merkel cell carcinoma
			5/2017: Urothelial carcinoma
Durvalumab	PDL-1	Imfinzi®	5/2017: Urothelial carcinoma